Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or Refractory Patients With Chronic Lymphocytic Leukemia
Sponsor: Eastern Cooperative Oncology Group
Listed as NCT00074282, this PHASE2 trial focuses on Leukemia and remains completed. Sponsored by Eastern Cooperative Oncology Group, it has been updated 11 times since 2005, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Jun 2023 [monthly]
Completed PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Mar 2019 — Dec 2020 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jun 2018 — Mar 2019 [monthly]
Unknown Status PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2
First recorded
Apr 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .